1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material
Duloxetine Delayed - release capsules USP
20 mg, 30 mg and 60 mg

Manufacturer
Lupin Limited
Goa 403722
INDIA

Distributor
Lupin Pharmaceuticals, Inc.
Harborplace Tower, 21st Floor
111, South Calvert Street
Baltimore, MD 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients
Duloxetine Hydrochloride USP
CAS
136434-34-9
20 mg, 30 mg and 60 mg

3. HAZARD IDENTIFICATION

Fire and Explosion
Expected to be non-combustible.

Health
The use of Monoamine Oxidase Inhibitors (MAOIs) intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. The use of duloxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated.

Starting duloxetine in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.

In clinical trials, duloxetine use was associated with an increased risk of mydriasis; therefore, its use should be avoided in patients with uncontrolled narrow-angle glaucoma.
### Environment
No information is available about the potential of this product to produce adverse environmental effects.

### 4. FIRST AID MEASURE

#### Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

#### Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

#### Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

#### Eye Contact
Flush eyes with plenty of water. Get medical attention.

### NOTES TO HEALTH PROFESSIONALS

#### Medical Treatment
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

#### OVERDOSAGE
There is no specific antidote to duloxetine, but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug.

An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients.

Activated charcoal may be useful in limiting absorption of duloxetine from the gastrointestinal tract. Administration of activated charcoal has been shown to decrease AUC and C\text{max} by an average of one-third, although some subjects had a limited effect of activated charcoal. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be beneficial.
In managing overdose, the possibility of multiple drug involvement should be considered. A specific caution involves patients who are taking or have recently taken duloxetine and might ingest excessive quantities of a TCA. In such a case, decreased clearance of the parent tricyclic and/or its active metabolite may increase the possibility of clinically significant sequelae and extend the time needed for close medical observation.

5. FIRE FIGHTING MEASURE

Fire and Explosion Hazards: Assume that this product is capable of sustaining combustion.

Extinguishing Media: Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Fire fighting Procedures: For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

Hazardous Combustion Products: Hazardous combustion or decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions: Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions: For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods: Collect and place it in a suitable, properly labelled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling: No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

Storage: Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical Form

Duloxetine is available as delayed release capsules in the following strengths, colors, imprints, and presentations:

<table>
<thead>
<tr>
<th>Features</th>
<th>20 mg</th>
<th>30 mg</th>
<th>60 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body color</td>
<td>Green</td>
<td>White</td>
<td>Green</td>
</tr>
<tr>
<td>Cap color</td>
<td>Green</td>
<td>Dark Blue</td>
<td>Dark Blue</td>
</tr>
<tr>
<td>Cap imprint</td>
<td>‘LU’</td>
<td>‘LU’</td>
<td>‘LU’</td>
</tr>
<tr>
<td>Body imprint</td>
<td>‘Q01’</td>
<td>‘Q02’</td>
<td>‘Q03’</td>
</tr>
<tr>
<td>Capsule number</td>
<td>4</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Bottles of 30</td>
<td>68180-294-06</td>
<td>68180-295-06</td>
<td>68180-296-06</td>
</tr>
<tr>
<td>Bottles of 90</td>
<td>68180-294-09</td>
<td>68180-295-09</td>
<td>68180-296-09</td>
</tr>
<tr>
<td>Bottles of 1000</td>
<td>68180-294-03</td>
<td>68180-295-03</td>
<td>68180-296-03</td>
</tr>
</tbody>
</table>

*equivalent to duloxetine base

10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinogenesis, Mutagenesis, Impairment of Fertility

**Carcinogenesis**

Duloxetine was administered in the diet to mice and rats for 2 years.

In female mice receiving duloxetine at 140 mg/kg/day (11 times the maximum recommended human dose [MRHD, 60 mg/day] and 6 times the human dose of 120 mg/day on a mg/m² basis), there was an increased incidence of hepatocellular adenomas and carcinomas. The no-effect dose was 50 mg/kg/day (4 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m² basis). Tumor incidence was not increased in male mice receiving duloxetine at doses up to 100 mg/kg/day (8 times the MRHD and 4 times the human dose of 120 mg/day on a mg/m² basis).

In rats, dietary doses of duloxetine up to 27 mg/kg/day in females (4 times the MRHD and 2 times the human dose of 120 mg/day on a mg/mg/m² basis) and up to 36 mg/kg/day in males (6 times the MRHD and 3 times the human dose of 120 mg/day on a mg/m² basis) did not increase the incidence of tumors.
Mutagenesis
Duloxetine was not mutagenic in the *in vitro* bacterial reverse mutation assay (Ames test) and was not clastogenic in an *in vivo* chromosomal aberration test in mouse bone marrow cells. Additionally, duloxetine was not genotoxic in an *in vitro* mammalian forward gene mutation assay in mouse lymphoma cells or in an *in vitro* unscheduled DNA synthesis (UDS) assay in primary rat hepatocytes, and did not induce sister chromatid exchange in Chinese hamster bone marrow *in vivo*.

Impairment of Fertility
Duloxetine administered orally to either male or female rats prior to and throughout mating at doses up to 45 mg/kg/day (7 times the maximum recommended human dose of 60 mg/day and 4 times the human dose of 120 mg/day on a mg/m² basis) did not alter mating or fertility.

12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

**IATA/ICAO - Not Regulated**

<table>
<thead>
<tr>
<th>IATA/ICAO</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IATA Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Packaging Group</td>
<td>N/A</td>
</tr>
<tr>
<td>IATA Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**IMDG - Not Regulated**

<table>
<thead>
<tr>
<th>IMDG</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IMDG Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Flash Point</td>
<td>N/A</td>
</tr>
<tr>
<td>IMDG Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**DOT - Not Regulated**

<table>
<thead>
<tr>
<th>DOT</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DOT Proper shipping Name</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT UN/ID No</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Hazard Class</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Flash Point</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Packing Group</td>
<td>N/A</td>
</tr>
<tr>
<td>DOT Label</td>
<td>N/A</td>
</tr>
</tbody>
</table>
15. **REGULATORY INFORMATION**

This Section Contains Information relevant to compliance with other Federal and/or state laws.

16. **OTHER INFORMATION**

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.